FOLH1 and cancer: Recently, 177Lu-PSMA-617 (Figure 5) was a novel promising radiopharmaceutical for nuclear imaging and TRT that is reported to be safe and can prolong overall survival in mCRPC patients.60-64 The development of this urea-based small PSMA inhibitor labeled with a beta particle-emitting radionuclide (Lu-177) was initially performed by a research group from the German Cancer Research Center (Deutsche Krebforschungszentrum, DKFZ) and its collaborating partner, the University Hospital of Heidelberg Germany in 2015.30